Pimasertib
Hematopoietic And Lymphoid System Neoplasm
Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
EMD Serono
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
31Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hematopoietic And Lymphoid System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pimasertib (this asset) | EMD Serono | P2 | CC · 46 |
| Adriamycin | OHSU Knight Cancer Institute | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Dexasone | City of Hope Medical Center | P3 | BB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BB |
| Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf) | Gamida Cell ltd | P3 | BB |
| Teclistamab | Janssen Pharmaceutical K.K. | P2 | BB |
| Bortezomib | OHSU Knight Cancer Institute | P4 | BB |
| Melphalan | Thomas Jefferson University | P2 | BB |
+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort
Other indications for Pimasertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | CCC · 50 |
| Breast Cancer | — | P1/2 | CC · 46 |
| Hormone Receptor-Positive Breast Cancer | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AdriamycinOHSU Knight Cancer InstituteBBB
- CyclophosphamideNational Cancer Institute (NCI)BB
- DexasoneCity of Hope Medical CenterBB
- FludarabineNational Cancer Institute (NCI)BB
- Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdBB
Citation
Floatz Terminal. Pimasertib in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pimasertib-hematopoietic-and-lymphoid-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →